Summary

How VLRX maps according to Revere

Sector Level Count
Industries 1
Sectors 2
Subsectors 6
Product/Service Groups 9

Specific product example for VLRX

Product Hierarchy
*Healthcare
Biopharmaceuticals
Endocrinology/Metabolism
Phase I/Phase II Clinical Stage Products

Company Highlights:

Market Cap. 130.850
Current Shares Outstnd. 14.9
Contact Name Stuart Z. Levine
Contact Phone (609)2353000
City, State Cranbury, NJ
Dividends Per Common Share 0.00
Dividend Yield n/a
SI %SHOUT 0.89
IH % Shares Outst. 20.82%
Number of Employees 101
Revenue Per Employee 128,391.8
Book Value Per Share 1.72
5 Year CAGR in Revenues % n/a
5 Year CAGR in Earnings % n/a
Asset Turnover 0.1
Fiscal Year End 12/31/2007
Next Reporting Period Mar, 2007

Business Description:

Valera Pharmaceuticals, Inc. (Valera) is a specialty pharmaceutical company concentrating on the development, acquisition and commercialization of products for the treatment of urological and endocrine conditions, diseases and disorders, including products that use its drug delivery technology. The Company?s first product, Vantas, was approved by the United States Food and Drug Administration (FDA) in October 2004. Other product candidates include Supprelin-LA, VP003 (Octreotide), VP004 (Naltrexone), VP005 (Anti-inflammatory), VP006 (rapid dissolve desmopressin), Valstar (Valrubicin) and Endoureteral Stent.

Chart:

Last Price 8.76
Price Chg. 0.00
Price Chg. % 0.00%
Open Price 8.74
High Price 8.89
Low Price 8.62
52w High Price 10.25
52w Low Price 4.49
Volume 81,748
30d Avg. Volume 25,816
VLRX - Chart
* Quotes delayed 20 minutes.

Products

Products Manufactured/Services Performed Details
*Healthcare
Biopharmaceuticals
Endocrinology/Metabolism
Phase I/Phase II Clinical Stage Products

Products:

  • VP003 (Octreotide)
Reproductive Disorders
Abnormal Puberty
Precocious
Gonadotropin Releasing Hormone (GnRH) Agonists

Products:

  • Supprelin-LA (Histrelin)
Obstetrics/Gynecology
Female Genital Disorders
Ovarian
Abnormal Puberty
Precocious
Gonadotropin Releasing Hormone (GnRH) Agonists

Products:

  • Supprelin-LA (Histrelin)
Oncology
Urology
Prostate Cancer
Palliative Agents
Gonadotropin Releasing Hormone (GnRH) Agonists

Products:

  • Vantas (Histrelin)
Urinary Bladder Cancer
Transitional Cell Carcinoma
Topoisomerase II Inhibitors

Products:

  • Valstar (Valrubicin)
Toxicology
Phase I/Phase II Clinical Stage Products

Products:

  • VP004 (Naltrexone)
Urology
Phase I/Phase II Clinical Stage Products

Products:

  • VP006 (Desmopressin Modified Release)
Research/Preclinical Stage Products

Products:

  • VP005 (Anti-Inflammatory)
Medical Devices
Urology
Surgical
General Procedure
Minimally Invasive/Cystoscopy
Dilation
Stents
Ureteral

Products:

  • Ureteral Stent

Key Financials

FY Ends December
Period Length/End 3 months
ending
12/31/2006 		3 months
ending
09/30/2006 		3 months
ending
12/31/2005 		12 months
ending
12/31/2006 		12 months
ending
12/31/2005 		12 months
ending
12/31/2004
Total Revenue 3.2 3.0 5.2 18.0 26.8 5.6
Gross Margin % 65.32 70.69 77.13 71.57 77.77 89.23
Operating Income -4.8 -5.0 -1.4 -15.1 -1.3 -12.3
Operating Margin % -149.52 -165.58 -27.47 -83.98 -4.91 -217.14
Tax Rate % 4.16 0.76 -5.29 1.46 -5.91 1.98
Income After Taxes -4.4 -4.7 -1.5 -13.9 -1.3 -12.0
Net Income Margin % -137.49 -155.46 -28.84 -77.59 -5.01 -212.95
F.D. EPS - Incl. Xord. Items -0.29 -0.31 -0.10 -1.03 -0.09 -1.22
Book Value Per Share 1.72 2.00 -2.15 1.72 -2.15 -2.03

Ratios

P/R Ratio (TTM) 7.28
P/E Ratio (TTM) n/a
Price To Free Cash Flow (TTM) -7.09
Price To Book Value 5.09
Net Assets to Market Cap. % 24.03%
Beta n/a
Days to Sell Inventory 484.6
Current Ratio 3.97
Quick Ratio 2.83
Interest Coverage n/a
Debt to Market Cap. % 0.01%
Return on Equity % -54.17
Return on Assets % -43.61
Return on Invested Capital % -57.73

Major Competitors

Name Trailing Revenue P/R Ratio (TTM) P/E Ratio (TTM) 1 Year Return % Overlap
Abbott Laboratories 22,476.3 4.02 52.57 40.94% 4
AstraZeneca plc (ADR) 26,475.0 3.24 14.19 8.68% 3
Bayer AG (ADR) 38,924.1 1.31 22.61 64.72% 3
Novartis AG (ADR) 36,749.0 3.60 25.15 1.00% 6
Pfizer Inc. 48,371.0 3.90 9.76 8.86% 3
Takeda Pharmaceutical Company Limited n/a n/a n/a 10.25% 0
Watson Pharmaceuticals, Inc. 1,979.2 1.41 n/a -0.66% 1
sanofi-aventis (ADR) 39,434.3 3.15 23.19 0.11% 3
Average 30,629.9 2.95 24.58 16.74% 3

Notes:

Customers

Name Last Quarter Financial Stats 1 YR Price Performance %
Y/Y Revenue Growth % Sequential Revenue Growth % Y/Y Margin Growth % Sequential Margin Growth %
AmerisourceBergen Corp. 14.14 6.92 9.83 0.00 17.84%
Average 14.14 6.92 9.83 0.00 17.84%

Notes:

Strategic Partners

Name Subtypes 1 YR Price Performance %
Alpex Pharma SA Research Collaboration n/a
AmerisourceBergen Corp. Distribution 17.84%
BioPro Pharmaceutical, Inc. Distribution, Out-licensing n/a
Key Oncologics (Pty) Ltd. Distribution, Out-licensing n/a
Paladin Labs Inc. Distribution, Out-licensing 48.89%
Shire plc (ADR) Distribution, Out-licensing 39.02%
Teva Pharmaceutical Industries Ltd (ADR) Distribution -7.01%
The Population Council Distribution, In-licensing n/a

Business/Geographical Segments